Pharmacology Flashcards
describe the structure of the alpha motor neurone
it is myelinated
cell bodies are located in the spinal cord and brainstem
what happens to the alpha motor neurone as it nears the muscle?
it divides into unmyelinated branches which end in a terminal bouton (NMJ)
synaptic vesicles containing ACh in the NMJ are located where?
active zones
where are nAChR located?
junctional folds that face active zones
pre-synaptic processes
- choline is transported into the terminal by choline transporter (symport with Na+)
- ACh is synthesised in the cytosol with acetyl coenzyme A by choline acetyltransferase
- ACh is concentrated in vesicles by vesicular ACh transporter
- AP causes depolarisation and Ca2+ enters and causes vesicles in active zones to undergo exocytosis
- ACh diffuses into the synaptic cleft and activates nAChR in endplate region
post-synaptic processes
- two ACh molecules activate each nAChR (pentamers of glycoprotein subunits surrounding central cation pore with a gate that only opens when ACh binds)
- channel is equally permeable to Na+ and K+, but does not conduct anions
- when the gate is open Na+ influxes at a faster rate than K+ effluxes
- causes simultaneous opening of many nAChR
what terminates ACh
hydrolysis by acetylcholinesterase (enzymes associated with the endplate membrane).
five examples of the clinical relevance of the NMJ
neuromyotonia Lambert-Eaton Myasthenia Syndrome Myasthenia gravis botulinum toxin curare-like compounds
describe neuromyotonia
autoantibodies to K+ channels leading to excitability
presentation of neuromyotonia
cramps
stiffness
slow relaxation
twitches
management of neuromyotonia
carbamazepine and phenytoin block Na+ channels
describe Lambert-Eaton myasthenic syndrome
autoantibodies to Ca2+ channels leading to reduced Ca2+ entry
presentation of LEMS (small cell lung carcinoma association)
muscle weakness
management of LEMS
anticholinesterases e.g. pyridostigmine
K+ channel blockers e.g. 3,4-diaminopyridine
describe myasthenia gravis
progressive muscle weakness during periods of activity, eye and eyelids
autoantibodies against nAChR in endplate region reducing functional challenges and AP